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Abstract
Objectives: The role of angiotensin II type 2 (AT2) receptor stimulation in the pathogenesis of insulin resistance is still
unclear. Therefore we examined the possibility that direct AT2 receptor stimulation by compound 21 (C21) might contribute
to possible insulin-sensitizing/anti-diabetic effects in type 2 diabetes (T2DM) with PPARc activation, mainly focusing on
adipose tissue.
Methods: T2DM mice, KK-Ay, were subjected to intraperitoneal injection of C21 and/or a PPARc antagonist, GW9662 in
drinking water for 2 weeks. Insulin resistance was evaluated by oral glucose tolerance test, insulin tolerance test, and uptake
of 2-[3H] deoxy-D-glucose in white adipose tissue. Morphological changes of adipose tissues as well as adipocyte
differentiation and inflammatory response were examined.
Results: Treatment with C21 ameliorated insulin resistance in KK-Ay mice without influencing blood pressure, at least
partially through effects on the PPARc pathway. C21 treatment increased serum adiponectin concentration and decreased
TNF-a concentration; however, these effects were attenuated by PPARc blockade by co-treatment with GW9662. Moreover,
we observed that administration of C21 enhanced adipocyte differentiation and PPARc DNA-binding activity, with a
decrease in inflammation in white adipose tissue, whereas these effects of C21 were attenuated by co-treatment with
GW9662. We also observed that administration of C21 restored b cell damage in diabetic pancreatic tissue.
Conclusion: The present study demonstrated that direct AT2 receptor stimulation by C21 accompanied with PPARc
activation ameliorated insulin resistance in T2DM mice, at least partially due to improvement of adipocyte dysfunction and
protection of pancreatic b cells.
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Introduction
The angiotensin (Ang) II type 1 (AT1) receptor mediates the
major effects of Ang II in the pathogenesis of insulin resistance and
subsequent type 2 diabetes mellitus (T2DM) [1]. AT1 receptor
blockers (ARBs) are known to improve insulin resistance and
reduce the new onset of diabetes [2–6]. When the AT1 receptor is
blocked by ARBs and unbound Ang II can act on the Ang II type
2 (AT2) receptor, stimulation of the AT2 receptor might be
involved in the effects of ARBs. AT2 receptor stimulation appears
to antagonize the signaling activated by AT1 receptor stimulation
in various tissues [7]; however, the role of AT2 receptor
stimulation in metabolic disorders is still unclear. We demonstrat-
ed that there was no apparent difference in insulin-mediated
glucose uptake into skeletal muscle between wild-type and AT2
receptor null mice, whereas insulin-induced glucose uptake in
white adipose tissue in AT2 receptor null mice was significantly
lower than that of control mice.3 It was reported that AT2
receptor-dependent Ang II signaling increases adipose cell mass
and glucose intolerance, thereby participating in the deleterious
effects of a high-fat diet [8]. Mitsuishi et al demonstrated that the
Ang II-induced reduction in muscle mitochondria in mice was
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partially, but significantly, reversed by blockade of either the AT1
receptor or AT2 receptor, associated with increased fat oxidation,
decreased muscle triglyceride, and improved glucose tolerance [9].
In terms of mitochondria, Abadir et al recently presented evidence
of age-related changes in mitochondrial Ang II receptor expres-
sion, i.e., increased mitochondrial AT1 receptor and decreased
AT2 receptor density, which was reversed by chronic treatment
with an ARB, and demonstrated that activation of the mitochon-
drial AT2 receptor increased NO production and probably
attenuated aging [10]. The availability of selective agonists of
the AT2 receptor could be useful in helping to resolve some of the
apparently conflicting results regarding the role of the AT2
receptor in various pathological conditions. The recent develop-
ment of selective non-peptidic AT2 receptor agonists has provided
new important tools for further evaluation of the roles of AT2
receptor stimulation in pathophysiological conditions and should
relaunch interest in studying the intracellular effects and regulation
of this receptor in various tissues [11,12].
Adipose tissue as an endocrine organ plays a crucial role in the
pathogenesis of insulin resistance and the onset of type 2 diabetes.
Adipose tissue contains renin, angiotensinogen and angiotensin-
converting enzyme (ACE), which results in increased production of
Ang II as a local regulator of adipose tissue functions. Previous
reports indicated that blockade of AT1 receptor stimulation
attenuated adipocyte dysfunction; however, the effects of AT2
receptor stimulation on adipose tissue functions are not yet clear.
We reported that the weight of both epididymal and retroperito-
neal adipose tissue in ApoE knockout (KO) mice with AT2
receptor deletion (AT2/ApoEKO) was greater than that in
ApoEKO mice after a high-cholesterol diet. In adipose tissue of
AT2/ApoEKO mice, the adipocyte number was decreased and
the expression of peroxisome proliferator-activated receptor
gamma (PPARc), CCAAT-enhancer-binding protein a (C/EBPa,
and adipocyte Protein 2 (aP2) was lower than that in ApoEKO
mice, in association with an increase in nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase activity, suggesting that
AT2 receptor stimulation in adipose tissue is involved in the
improvement of adipocyte differentiation and adipose tissue
dysfunction in an atherosclerotic model [13]. It was previously
reported that the AT2 receptor also mediates the effect of Ang II to
induce the production and release of prostacyclin from adipocytes,
which in turn stimulates differentiation of adipose precursor cells
[14,15]. Yvan-Charvet L et al also reported that adipocyte
hypertrophy and increased lipogenic gene expression induced by
adipose angiotensinogen overproduction was prevented by dele-
tion of the AT2 receptor [16]. These results led us to examine the
roles of direct AT2 receptor stimulation by compound 21 (C21) in
adipose tissue in terms of glucose intolerance using type 2 diabetic
mice KK-Ay.
PPARc, a nuclear transcription factor, plays an important role
in regulation of adipocyte differentiation, insulin resistance, and
inflammation [17]. In addition, large clinical studies have
demonstrated that a PPARc agonist had beneficial effects on not
only glycemic control but also preventing atherosclerotic disease
[18–21]. Possible crosstalk between PPARc and the AT1 receptor
such as a decrease in AT1 receptor promoter activity and AT1
receptor expression by PPARc activation has been suggested
[22,23]. It has also been reported that AT1 receptor blockade
decreases NF-kB activation, with PPARc activation in the
vasculature [24]. AT1 receptor stimulation activates ERK, and
PPARc stimulation inhibits this ERK activation in VSMC [25].
On the other hand, it is reported that Ang II induces PPARc
activation in PC12W cells via AT2 receptor activation [26].
Accordingly, we hypothesized that AT2 receptor stimulation by
C21 might contribute to possible insulin-sensitizing/anti-diabetic
effects in type 2 diabetes, with PPARc activation. It is also
clinically important to investigate the possibility that crosstalk
between AT2 receptor stimulation and PPARc activation may
regulate adiopocyte function and insulin resistance, and therefore
we also examined this possibility in this study.
Methods
Animal and treatment
Eight-week-old adult male KK-Ay mice (CLEA, Tokyo, Japan)
were used in this study. They were housed in an air conditioned
room at 25uC with a 12-h light/12-h dark cycle. They were given
a standard diet (MF, Oriental Yeast, Tokyo, Japan) and water ad
libitum. Compound 21 was provided by Vicore Pharma (Gothen-
burg, Sweden). KK-Ay mice were subjected to intraperitoneal
injection of C21 (10 mg/kg per day) dissolved in 100 ml of
phosphate buffered saline (PBS) for 2 weeks. Some KK-Ay mice
treated with C21 were concurrently administered GW9662, a
PPARc antagonist, at a dose of 0.35 mg/kg per day in drinking
water. The control mice were given intraperitoneal injection of an
equivalent volume of vehicle as the experimental group. Systolic
blood pressure (SBP) was measured by the tail-cuff method (MK-
2000ST, Muromachi Kikai, Co. Ltd., Tokyo, Japan) as described
previously [27]. All procedures were performed in accordance
with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals, and reviewed and approved by the Animal
Studies Committee of Ehime University.
Oral glucose tolerance test and insulin tolerance test
Oral glucose tolerance test (OGTT) was performed after 16-
hour overnight fasting [28]. Glucose solution (2 g/kg) was
administered orally, and a small amount of blood was obtained
from the orbital sinus or tail vein without anesthesia at 0, 30, 60
and 120 min after glucose loading. For insulin tolerance test (ITT),
mice were given an intraperitoneal injection of 0.5 U/kg insulin
solution (NovoRapid, Novo Nordisk, Bagsvaerd, Denmark) after
4-hour fasting. Blood glucose concentration was determined by
glucose dehydrogenase pyrroloquinolinequinone method (Free-
style, Nipro, Osaka, Japan). Serum insulin concentration was
measured by enzyme-linked immunosolvent assay (ELISA) (Ultra
Sensitive Rat Insulin kit, Morinaga Institute of Biological Science,
Kanagawa, Japan).
Morphological analysis of adipose tissue and pancreatic
tissue
Epididymal and retroperitoneal white adipose tissue was taken,
fixed with formalin, and paraffin-embedded sections were
prepared [29]. After staining the sections with fuchsin, adipocyte
number in three microscopic fields was counted and expressed as
the cell number per mm2. Pancreatic tissue was taken similarly,
fixed with formalin, and paraffin-embedded sections were stained
with Gomori’s aldehyde-fuchsin to visualize b cell granules in islets
[30]. The ratio of stained area (b cell area) was calculated using
computer-imaging software (Densitograph; ATTO Corporation).
Values were obtained from five different mice in each group.
Measurement of serum insulin, adiponectin and TNF-a
concentrations
Serum concentrations of insulin (Ultra Sensitive Rat Insulin kit,
Morinaga Institute of Biological Science, Kanagawa, Japan),
adiponectin (Mouse/Rat High Molecular Weight Adiponectin
ELISA KIT, AKMAN-011, Shibayagi, Gunma, Japan), and
Compound 21 and Type 2 Diabetes
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tumor necrosis factor (TNF)-a (Mouse TNF-a ELISA KIT,
AKMTN-011, Shibayagi, Gunma, Japan) were measured using
commercially available kits.
Measurement of rate constant of net tissue uptake of 2-
[3H]deoxy-D-glucose
Uptake of 2-[3H]deoxy-D-glucose (2-[3H]DG) in peripheral
tissues was measured as previously reported [31]. Epididymal and
retroperitoneal white adipose tissue was rapidly dissected and
weighed. The rate constant of net tissue uptake of 2-[3H]DG was
calculated as described previously [32].
Quantitative reverse-transcription polymerase chain
reaction (RT-PCR)
Real-time quantitative reverse-transcription polymerase chain
reaction (PCR) was performed with a SYBR Premix Ex Taq
(Takara Bio Inc., Japan). mRNAs were prepared from epididymal
and retroperitoneal white adipose tissue after treatment with or
without C21 and/or GW9662. PCR primers were as follows: 59-
CACCCAAGGGAACTTGTGCAG-39 (forward) and 59-
GGTCGTAGGTGAAGAGAACGG-39 (reverse) for adiponectin,
59-TGGAGACCGCCCAGGCTTG-39 (forward) and 59-
GTCTGTCATCTTCTGGAGCACCTT-39 (reverse) for
PPARc, 59-CAAAGCCAAGAAGTCGGTGGACAA-39 (for-
ward) and 59-TCATTGTGACTGGTCAACTCCAGC-39 (re-
verse) for C/EBPa, 59-AACACCGAGATTTCCTT-39 (forward)
and 59-ACACATTCCACCACCAG-39 (reverse) for aP2, 59-
CGAGTGACAAGCCTGTAGCC-39 (forward) and 59-
GGTGAGGAGCACGATGTCG-39 (reverse) for tumor necrosis
factor-a (TNF-a), 59-TTAACGCCCCACTCACCTGCTG-39
(forward) and 59-GCTTCTTTGGGACACCTGCTGC-39 (re-
verse) for monocyte chemoattractant protein-1 (MC-1), 59-
CCACTTCACAAGTCGGAGGCTTA-39 (forward) and 59-
GCAAGTGCATCATCGTTGTTCATAC-39 (reverse) for inter-
leukin-6 (IL-6), 59-ATGTAGGCCATGAGGTCCAC-39 (for-
ward) and 59-TGCGACTTCAACAGCAACTC-39 (reverse) for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
DNA-binding activity of PPARc in adipose tissue
Nuclear extract from adipose tissue was prepared using a
nuclear extract kit (Sigma–Aldrich, Japan) after homogenization of
adipose tissue with a glass homogenizer according to the
manufacturer’s protocol. DNA-binding of PPARc was determined
with a DNA-binding ELISA kit (TransAMTM PPARc, Active
Motiv, Carlsbad, CA). The kit is designed to detect PPARc protein
in nuclear extract, which binds to PPARc response element
immobilized at the bottom of the 96-well plate, using specific
antibodies conjugated to horseradish peroxidase. Five micrograms
of protein from each nuclear extract was applied to the assay, and
DNA-binding of PPARc was determined.
Statistical analysis
All values are expressed as mean 6 standard error in the text
and figures. Data were evaluated by analysis of variance (ANOVA)
followed by post-hoc analysis for multiple comparisons. A
difference with p,0.05 was considered significant.
Results
Effect of compound 21 on blood glucose, serum insulin,
adiponectin, and TNF-a concentrations
Treatment of KK-Ay with an AT2 receptor agonist, C21
(10 mg/kg per day), for 14 days did not change systolic blood
pressure compared with that in control KK-Ay mice. (data not
shown) The increase in body weight of KK-Ay was attenuated
with C21 treatment, whereas this effect of C21 was attenuated by
GW9662 administration (Table 1 and 2). Food intake was not
different in each group. Treatment with C21 significantly reduced
blood glucose concentration and serum insulin concentration in
the fed condition compared with those in control KK-Ay mice
(Figure 1A and 1B). The decreases of blood glucose and serum
insulin concentrations by C21 treatment were attenuated by co-
administration of GW9662, whereas treatment with GW9662
alone did not affect blood glucose and serum insulin concentra-
tions. We also observed that C21 treatment increased serum
adiponectin concentration, but decreased serum TNF-a concen-
tration compared with those in control KK-Ay mice (Figure 1C
and 1D). GW9662 treatment attenuated the C21-mediated
increase of serum adiponectin concentration and the decrease of
serum TNF-a concentration, whereas treatment with GW9662
alone did not affect them.
Effect of compound 21 on glucose intolerance and
insulin sensitivity
In OGTT, the basal blood glucose concentration after 16-hour
fasting did not differ between each group, whereas the peak of the
glucose rise in response to a glucose load was lower and the
decrease of blood glucose concentration was faster in mice treated
with C21 compared with control and GW9662-treated KK-Ay
mice (Figure 2A). Serum insulin concentration was lower in mice
treated with C21 compared with control and GW9662-treated
mice. Moreover, we observed that C21 treatment increased serum
insulin concentration at 30 minutes after a glucose load
(Figure 2B). The decrease of blood glucose concentration and
Table 1. Effect of compound 21 on body weight in KK-Ay
mice.
Body weight (g)
Group Baseline Day 7 Day 14
Control 38.662.2 39.762.6 41.062.8
C21 38.361.7 38.761.1*{ 39.361.1*{{
C21+GW9662 38.661.4 39.161.6 39.960.7*
GW9662 38.561.9 39.562.2 41.362.5
Animals were fed normal standard diet for 2 weeks. Values are mean6SEM of
15 to 20 mice for each group. C21, compound 21.
*p,0.01 vs. control;
{p,0.01 vs. GW9662;
{p,0.01 vs. C21+GW9662.
doi:10.1371/journal.pone.0048387.t001
Table 2. Effect of compound 21 on food intake in KK-Ay
mice.
Group Food intake (g/day)
Control 6.760.7
C21 6.460.6
C21+GW9662 6.360.7
GW9662 6.560.6
Animals were fed normal standard diet for 2 weeks. Values are mean6SEM of
15 to 20 mice for each group. C21, compound 21.
doi:10.1371/journal.pone.0048387.t002
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the increase of serum insulin concentration after a glucose load by
C21 treatment were attenuated by GW9662 administration
(Figure 2A and 2B). In ITT, the decrease of blood glucose
concentration by insulin injection was further enhanced in the
C21-treated group, while this increase of insulin response by C21
treatment was inhibited by GW9662 treatment (Figure 2C).
Effect of compound 21 on glucose uptake in adipose
tissue of KK-Ay mice
Administration of C21 significantly increased 2-[3H]DG uptake
in white adipose tissue with or without insulin stimulation
(Figure 3). The enhancement of 2-[3H]DG uptake after insulin
injection by C21 was attenuated by co-administration of GW9662
in white adipose tissue, whereas treatment with GW9662 alone did
not affect 2-[3H]DG uptake.
Adipose tissue weight and adipocyte size after treatment
with compound 21
To examine the possible mechanism of the C21-mediated
improvement of glucose intolerance in KK-Ay mice, we focused
on adipose tissue. Treatment with C21 for 14 days significantly
decreased the ratio of epididymal and retroperitoneal adipose
tissue weight to body weight, whereas this ratio became higher
with GW9662 co-treatment (Table 3, Figure 4A and 4B). On
histological analysis, mean adipocyte size in white adipose tissue
was smaller in the C21-treated group, and consequently the
number of adipocytes was increased by C21 treatment
(Figure 4C, 4D and 4E). The C21-mediated decrease in
adipocyte size and increase in adipocyte number were attenuated
by GW9662 administration, while GW9662 treatment alone did
not influence adipocyte size or number.
Effect of compound 21 on expression of adipocyte
differentiation markers and DNA-binding activity of
PPARc in white adipose tissue
Treatment with C21 increased the mRNA expression of PPARc
in epididymal and retroperitoneal adipose tissue of KK-Ay mice
(Figure 5A). We next examined DNA-binding activity of PPARc
in these adipose tissues of KK-Ay mice and observed that DNA-
binding activity of PPARc was enhanced in C21-treated mice
(Figure 5B). These increases in PPARc expression and DNA-
binding activity of PPARc were inhibited by co-administration of
GW9662, whereas treatment with GW9662 did not influence
these parameters. The expression of adipocyte differentiation
markers, such as C/EBPa and aP2, was increased by C21
treatment (Figure 5C and 5D). GW9662 administration
attenuated the C21-mediated increase in expression of C/EBPa
and aP2, whereas treatment with GW9662 alone did not influence
this.
Effect of compound 21 on expression of adiponectin,
inflammatory cytokines, and angiotensin II receptors in
white adipose tissue
C21 treatment enhanced mRNA expression of adiponectin in
epididymal and retroperitoneal adipose tissue compared with that
in control KK-Ay mice, and this increase was attenuated by co-
administration of GW9662 (Figure 6A). Treatment with C21
decreased mRNA expression of inflammatory cytokines, such as
TNF-a, IL-6, and MCP-1, which was inhibited by GW9662
treatment (Figure 6B, 6C, and 6D). In contrast, treatment with
GW9662 alone did not change mRNA expression of these
inflammatory markers. There was no significant difference in
Figure 1. Effect of compound 21 administration on blood glucose, insulin, and adipocytokines in KK-Ay mice. Concentrations of blood
glucose (A) and serum insulin (B) in KK-Ay mice treated with compound 21 (C21). KK-Ay mice were treated as described in ‘Methods’. Some KK-Ay
mice treated with C21 were concurrently administered GW9662, a PPARc antagonist. Blood samples were obtained under a fed condition. Effect of
compound 21 on concentrations of adiponectin (C) and TNF-a (D) in KK-Ay mice. Blood samples were obtained after 16 hours of fasting.
Concentrations of serum adiponectin and TNF-a in KK-Ay mice were measured by ELISA. Data are expressed as mean 6 SEM. n= 10 for each group.
*p,0.01 vs. control.
doi:10.1371/journal.pone.0048387.g001
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mRNA expression of the AT1 and AT2 receptors in white adipose
tissue among the four groups (Figure 6E and 6F).
Recovery of b cell number in pancreas after compound
21 treatment
We observed that C21 treatment increased insulin concentra-
tion after a glucose load, and we assumed that C21 could prevent
pancreatic b cell damage in KK-Ay. The number of b cells in
pancreas islets detected by aldehyde-fuchsin staining was increased
in C21-treated mice compared with control and GW9662-treated
mice (Figure 7A and 7B). This increase in b cell number in the
pancreas by C21 treatment was attenuated by GW9662 admin-
istration, while treatment with GW9662 alone did not influence
these parameters.
Discussion
The roles of AT2 receptor stimulation in the pathogenesis of
insulin resistance and functions of adipose tissue in T2DM are still
an enigma. Most studies addressing the involvement of the AT2
receptor in a variety of experiments have been performed in
genetically altered, either AT2 receptor-deficient or AT2 receptor-
overexpressing mice with or without ARB treatment, and
Figure 2. Effect of compound 21 administration on glucose intolerance in KK-Ay mice. Effect of administration of compound 21 (C21) on
concentrations of blood glucose (A) and serum insulin (B) in oral glucose tolerance test (OGTT), and glucose concentration in insulin tolerance test
(ITT) (C) in KK-Ay mice. Male KK-Ay mice were treated as described in ‘Methods’. Some KK-Ay mice treated with C21 were concurrently administered
GW9662, a PPARc antagonist. OGTT and ITT were performed after 16 hours and 4 hours of fasting, respectively (n = 8–10 per group). Data are
expressed as mean 6 SEM. *p,0.01 vs. control; {p,0.01 C21 vs. C21+GW9662.
doi:10.1371/journal.pone.0048387.g002
Figure 3. Effect of compound 21 administration on glucose uptake in KK-Ay mice. Rate constant of 2-[3H]deoxy-D-glucose (2-[3H]DG)
uptake in epididymal (Epi) and retroperitoneal (Retro) white adipose tissue. Rate constant of 2-[3H]DG uptake was determined with or without insulin
(1.0 U/kg) injection as described in ‘‘Methods’’ (n = 6–8 per group). Data are expressed as mean 6 SEM. *p,0.01 vs. control (insulin2); {p,0.01 vs.
control (insulin+). C21, compound 21.
doi:10.1371/journal.pone.0048387.g003
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unfortunately these experimental approaches have yielded con-
flicting results. Moreover, PD123319, a widely used AT2 receptor
antagonist, acts nonselectively at a higher dose [33] and likewise,
CGP42112, a widely used AT2 receptor agonist, has both agonistic
and antagonistic actions depending on its dose used. These
findings made it difficult to properly assess AT2 receptor actions,
especially in vivo. For example, the effect of the AT2 receptor on
cardiac function after myocardial infarction is controversial, due to
lack of an experimental tool to directly stimulate the AT2 receptor
under in vivo conditions [34]. A novel non-peptide AT2 receptor
agonist, C21, is a nonpeptidergic agent that has high affinity and
selectivity for the AT2 receptor [35]. Therefore, it can be expected
that C21 will allow the effects of the AT2 receptor in cardiac
hypertrophy to be studied by means of direct, selective AT2
receptor stimulation, which will hopefully help to overcome
current controversies [36]. Consistent with this, Kaschina et al
reported that treatment with C21 significantly improved systolic
and diastolic ventricular function in the rat after myocardial
infarction, suggesting that direct AT2 receptor stimulation may be
a novel therapeutic approach to improve cardiac function after
myocardial infarction through anti-apoptotic and anti-inflamma-
tory mechanisms [37]. In keeping with these results, we used C21
to elucidate the roles of direct AT2 receptor stimulation in the
pathogenesis of insulin resistance in T2DM, mainly focusing on
adipose tissue.
We observed that treatment with a non-hypotensive dose of
C21 decreased adipose tissue weight/body weight, and that C21
treatment decreased blood glucose and serum insulin concentra-
tions in non-fasting condition in KK-Ay mice. It is well known that
insulin resistance is a major metabolic feature of obesity and plays
Figure 4. Effect of compound 21 administration on adipose tissue weight and adipocyte size in KK-Ay mice. KK-Ay mice were treated
as described in ‘Methods’. Ratio of white adipose tissue (WAT) weight to body weight (BW) in epididymal (Epi) WAT (A) and retroperitoneal WAT
(Retro) (B) (n = 10 for each group). Representative microscopic photos of adipose tissue (C) and measurement of adipocyte size (D) and Mean
adipocyte number (E) in KK-Ay mice. Formalin-fixed, paraffin-embedded sections of Epi and Retro white adipose tissue were stained by fuchsin.
Adipocyte size was measured in three microscopic fields (40–60 adipocytes per field) for each section using computer-imaging software. Data are
expressed as mean 6 SEM. n = 5 to 6 per group. *p,0.01 vs. control. C21, compound 21.
doi:10.1371/journal.pone.0048387.g004
Table 3. Effect of compound 21 on adipose tissue weight in
KK-Ay mice.
Adipose tissue weight (g)
Group Epi Retro
Control 1.6060.10 0.8960.12
C21 1.2260.06*{{ 0.4960.07*{{
C21+GW9662 1.3660.08*{ 0.6060.08*{
GW9662 1.6960.07 0.9360.08
Values are mean6SEM of 10 mice for each group. C21, compound 21; Epi,
epididymal; Retro, retroperitoneal.
*p,0.01 vs. control;
{p,0.01 vs. GW9662;
{p,0.01 vs. C21+GW9662.
doi:10.1371/journal.pone.0048387.t003
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a key role in the etiology of T2DM. We also showed that C21
treatment attenuated the rise of blood glucose concentration after
a glucose load, with an increase of serum insulin concentration.
Consistent with these results, we demonstrated that C21 treatment
increased serum adiponectin and decreased TNF-a concentra-
tions, and enhanced adipocyte differentiation, with increases in
mRNA expression of PPARc, C/EBPa and aP2, and PPARc
activation. These results, including a previous report, [13] suggest
that AT2 receptor stimulation could enhance adipocyte differen-
tiation, thereby resulting in the improvement of glucose intoler-
ance. However, it should be noted that the lack of hypotensive
effects as judged by the tail cuff method does not completely
exclude a possible effect of C21 on blood pressure because the tail
cuff method does not give accurate readings of diastolic pressure
nor does it not provide for 24 hour measurements of blood
pressure.
Many lines of evidence have indicated that obesity is closely
linked to a chronic inflammatory state, which contributes to
metabolic disorders [38]. Adipose tissue is thought to directly
exaggerate insulin resistance and to trigger inflammation by
secreting adipokines such as IL-6 and TNF-a [1]. Thus, adipose
tissue dysfunction can tend toward to a chronic inflammatory state
through imbalance of pro-inflammatory and anti-inflammatory
activities [39]. Moreover, inflammatory cytokines regulate the
differentiation of adipocytes and their function, resulting in
worsening of insulin resistance. For instance, TNF-a inhibits
adipogenesis by preventing the induction of PPARc and C/EBPa
expression [40]. We observed that C21 treatment increased serum
adiponectin concentration and decreased serum TNF-a concen-
tration, and that administration of C21 enhanced mRNA
expression of adiponectin and decreased mRNA expression of
TNF-a, IL-6 and MCP-1 in white adipose tissue. Moreover, TNF-
a is known to directly inhibit insulin signaling, resulting in insulin
resistance [41]. Consistent with these findings, we observed that
C21 treatment significantly increased 2-[3H]DG uptake in white
adipose tissue. These results are consistent with the possibility that
AT2 receptor stimulation by C21 and or some other actions of
C21 may attenuate inflammation in white adipose tissue and
thereby help enhance adipocyte differentiation and improve
insulin resistance. Addressing more detailed mechanisms is
important for future clinical application of direct AT2 receptor
stimulation.
AT2 receptor activation is reported to induce PPARc activation
in PC12W cells [26], leading us to hypothesize that AT2 receptor-
mediated improvement of glucose intolerance is at least in part due
to PPARc activation. We observed that AT2 receptor stimulation
by C21 enhanced not only PPARc expression but also DNA-
binding activity of PPARc in white adipose tissue of KK-Ay,
suggesting that the possible crosstalk between AT2 receptor
stimulation and PPARc activation could be involved in the
attenuation of insulin resistance in concert with the regulation of
adipocyte differentiation and functions. Accordingly, we demon-
strated that C21-mediated improvement of insulin resistance,
adipocyte differentiation, and inflammation in adipose tissue were
blunted by PPARc blockade with GW9662, supporting the idea
that direct AT2 receptor stimulation by C21 ameliorated insulin
resistance in T2DM model mice at least partially due to PPARc
activation. In contrast, in adipose tissue, the possibility exists that
Figure 5. Effects of compound 21 administration on adipocyte differentiation in KK-AY mice. Adipocyte differentiation markers and
DNA-binding activity of peroxisome proliferator-activated receptor c (PPARc) in epididymal (Epi) and retroperitoneal (Retro) white adipose tissue of
KK-Ay mice were determined. mRNA expression (A) and in vivo DNA-binding activity of PPARc (B). mRNA expressions of CCAAT-enhancer-binding
protein a (C/EBPa) (C) and adipocyte Protein 2 (aP2) (D). Data are expressed as mean 6 SEM. n = 5 to 6 per group. *p,0.05 vs. control. C21,
compound 21.
doi:10.1371/journal.pone.0048387.g005
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Figure 6. Effects of compound 21 administration on inflammation in KK-Ay mice. mRNA expressions of adiponectin (A), tumor necrosis
factor-a (TNF-a) (B), interleukin-6 (IL-6) (C), monocyte chemoattractant protein-1 (MCP-1) (D), AT1 receptor (E) and AT2 receptor (F) in epididymal
(Epi) and retroperitoneal (Retro) white adipose tissue of KK-Ay mice. Data are expressed as mean 6 SEM. n = 5 to 6 per group. *p,0.05 vs. control.
C21, compound 21.
doi:10.1371/journal.pone.0048387.g006
Figure 7. Changes in b cells in pancreatic islets by compound 21 treatment in KK-Ay mice. KK-Ay mice were treated as described in
‘Methods’. The pancreas was taken, fixed with formalin and embedded in paraffin. Sections were subjected to aldehyde-fuchsin staining to detect b
cells in pancreatic islets. (A) Reproducible microscopic photos of pancreas. Magnification:6100. (B) Quantification of stained b cell area. Area was
measured using computer-imaging software as described in ‘Methods’ and expressed as the ratio of b cell area to total islet area. n = 5 to 6 in each
group. *p,0.01 vs. control. C21, compound 21.
doi:10.1371/journal.pone.0048387.g007
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decreased PPARc expression improved insulin sensitivity, as
demonstrated in PPARc-deficient mice [42]. Moreover, decreas-
ing PPARc activity by a specific antagonist was shown to improve
insulin sensitivity, accompanied by adipocyte hypotrophy and
hyperplasia as observed in PPARc heterozygous mice [43]. These
apparent discrepancies might be dependent on differences in
experimental models. It would be intriguing to investigate the roles
of possible interaction of the AT2 receptor and PPARc in the
pathogenesis of diabetes.
We observed that C21 treatment increased serum insulin
concentration in response to a glucose load. Both AT1 and AT2
receptors are present in various pancreatic tissues, and Ang II has
been proposed to have important roles in the pancreas, such as
regulating islet b cell insulin biosynthesis and glucose-stimulated
insulin release [44]. AT1 blockade by ARBs has been reported to
have beneficial effects on the pancreas in various diabetes model
mice [45–47]. However, the role of the AT2 receptor in the
pancreas is still unclear. Therefore, we examined the possibility
that AT2 receptor stimulation could protect against b cell damage
in the diabetic pancreas and increase insulin production and
secretion. We demonstrated that C21 treatment increased the
number of b cells in pancreas islets compared with that in control
KK-Ay mice. We speculate the reason why the C21 reduced
insulin levels in the fed state but increased insulin levels in the
OGTT might be due to the preservation of pancreatic b cell
number and enhancement of glucose uptake in white adipose
tissues, resulting in increases in insulin secretory response and
decreases in insulin resistance. The detailed mechanisms of AT2
receptor-mediated pancreatic b cell protection in diabetic mice
remain to be elucidated. One possible mechanism is a C21-
mediated decrease in TNF-a, since TNF-a is known to induce
apoptotic cell death in mouse primary b cells and insulinoma cell
lines [48], and inhibit glucose-stimulated insulin transcription and
secretion observed in the HIT-T15 pancreatic b cell line [49]. We
also showed that treatment with GW9662 attenuated the C21-
mediated increase of serum insulin concentration after a glucose
load and the preservation of b cell number in the pancreas in KK-
Ay. Activation of PPARc has been shown to regulate transcription
of several key b cell genes involved in glucose sensing, b cell
development, glucose-stimulated insulin secretion, and insulin
gene transcription. Activation of these targets leads to enhanced
insulin secretion and gene expression in the diabetic state [50].
These data, including our results, suggest that the possible
crosstalk between AT2 receptor stimulation and PPARc activation
may also be involved in pancreatic b cell function.
It should be acknowledged that the current studies do not prove
that any of the metabolic effects of C21 are necessarily mediated
by AT2 receptor stimulation because we have not excluded the
possibility that C21 might be functioning as a direct agonist of
PPAR isoforms including PPARc and PPARa and PPARd. Future
studies will be required to determine the extent to which the
metabolic effects of C21 are mediated by its interaction with AT2
as opposed to its possible interaction with other receptors such as
PPARc, PPARa, and PPARd, etc.
Taken together, the current results demonstrate that the AT2
agonist C21 improves insulin resistance in T2DM mice in
association with enhanced adipocyte differentiation and possibly
function, and with protection of b cells in pancreas islets. These
effects of C21 were blunted by PPARc blockade, suggesting a role
for PPAR activation in mediating the metabolic actions of C21.
The extent to which the metabolic effects of C21 are mediated by
its direct interaction with AT2 and or by direct interaction with
other receptors such as PPARc, PPARa, and PPARd remains to
be determined. In any case, molecules like C21 may hold promise
as potential therapeutic options for the management of insulin
resistance and T2DM in the future.
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